(estradiol and norethindrone acetate) Tablets
CARDIOVASCULAR AND OTHER RISKS
The estrogen plus progestin sub-study of the Women's Health Initiative (WHI) reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) per day, relative to placebo. (See Clinical Studies and WARNINGS, Cardiovascular Disorders and Malignant Neoplasms, Breast Cancer.)
The estrogen-alone sub-study of the WHI reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 6.8 years and 7.1 years, respectively, of treatment with oral conjugated estrogens (CE 0.625 mg) per day, relative to placebo. (See Clinical Studies and WARNINGS, Cardiovascular Disorders.)
The Women's Health Initiative Memory Study (WHIMS), a sub-study of the WHI study, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with CE 0.625 mg combined with MPA 2.5 mg and during 5.2 years of treatment with CE 0.625 mg alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. (See Clinical Studies, WARNINGS, Dementia and PRECAUTIONS, Geriatric use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these trials, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
Mimvey (estradiol and norethindrone acetate) 1 mg/0.5 mg is a single tablet for oral administration containing 1 mg of estradiol and 0.5 mg of norethindrone acetate and the following inactive ingredients: lactose, colloidal silicon dioxide, copovidone, hypromellose, magnesium stearate, polyethylene glycol, polysorbate 80, starch and titanium dioxide.
Estradiol (E2) is a white or almost white crystalline powder. Its chemical name is estra-1, 3, 5 (10)-triene-3, 17β-diol hemihydrate. The structural formula is as follows:
C18H24O2, ½ H2O Molecular Weight: 281.4
Norethindrone acetate (NETA) is a white or yellowish-white crystalline powder. Its chemical name is 17β-acetoxy-19-nor-17α-pregn-4-en-20-yn-3-one. The structural formula of NETA is as follows:
C22H28O3 Molecular Weight: 34 0.5
Last reviewed on RxList: 4/1/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Mimvey Information
Report Problems to the Food and Drug Administration
Find out what women really need.